Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 9Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 1

Interventions

regorafenib 3Sunitinib 2Ramucirumab 2Oxaliplatin 2Fluorouracil 2zenocutuzumab 1zanidatamab 1ulixertinib 1trifluridine tipiracil drug combination 1sodium thiosulfate 1selpercatinib 1ripretinib 1peginterferon alfa-2a 1pegilodecakin 1onvansertib 1omburtamab I-131 1guselkumab 1futibatinib 1derazantinib 1balstilimab 1avapritinib 1Tenofovir 1Taxes 1Proton Pump Inhibitors 1Paclitaxel 1Melphalan 1Leucovorin 1Laparoscopy 1Imatinib Mesylate 1IMM-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × futibatinib × Gastrointestinal × Clear all
NCT04507503 2026-03-10

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Taiho Oncology, Inc.

Approved for marketing
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡